pre-IPO PHARMA

COMPANY OVERVIEW

Terns Pharmaceuticals is a global biopharmaceutical company committed to discovering and developing molecularly-targeted, oral, small molecule drugs to treat liver disease and cancer. The company combines expertise in disease biology and medicinal chemistry with a capital-efficient drug discovery model and extensive clinical development capabilities in China to advance its growing pipeline of drugs that are optimized against clinically-validated targets.


LOCATION

  • San Mateo, CA, USA
  • Shanghai, , China

  • THERAPEUTIC AREAS

  • Liver Disease
  • Oncology

  • WEBSITE

    https://ternspharma.com


    CAREER WEBSITE

    https://ternspharma.com/careers/


    SOCIAL MEDIA


    INVESTORS

    decheng-capital lilly-asia-ventures orbimed vivo-capital


    PRESS RELEASES


    Feb 1, 2021

    Terns Pharmaceuticals, Inc. Announces Proposed Initial Public Offering of Common Stock


    Nov 16, 2020

    Terns Pharmaceuticals Appoints Industry Veteran Bryan Yoon as Chief Operating Officer and General Counsel


    Oct 22, 2020

    Terns Pharmaceuticals to Present Clinical Data on Improved TERN-101 Tablet Formulation at the Paris NASH Digital Experience


    Oct 14, 2020

    Terns Pharmaceuticals to Present Positive Data on Single-Agent and Combination NASH Programs at The Liver Meeting Digital Experience 2020


    Sep 10, 2020

    Terns Pharmaceuticals Receives Fast Track Designation for TERN-201 as a Treatment for NASH


    For More Press Releases


    Google Analytics Alternative